Series A14 November 2025

T-Therapeutics secures £24.3m Series A follow-on investment from BGF and Tencent

BGF and Tencent join existing shareholders to support the biotechnology company in advancing its drug development programmes.

£24.3MSeries A

T-Therapeutics develops next-generation T cell receptor therapeutics to treat cancer and autoimmune diseases. The biotechnology company spun out of the University of Cambridge to advance its proprietary drug development programmes.

Biotechnology enterprise T-Therapeutics has secured £24.3m in a Series A extension financing round, adding new backers BGF and Tencent to its existing syndicate. The capital will support the company as it advances its therapeutic programmes targeting solid tumours and immune system disorders through its proprietary discovery platform.

The latest injection brings the total raised in the Series A round to £69m. The enterprise continues to draw backing from prominent life sciences investors including Sofinnova Partners, F-Prime Capital, Digitalis Ventures, Cambridge Innovation Capital, Sanofi Ventures and the University of Cambridge Venture Fund.

From the founder

"We are delighted to have significantly added to our Series A financing, which we see as a strong validation of both our technology and our progress to date. I would like to thank Tencent and BGF for their belief in our potential, as well as all our existing investors for their continued support."

Theodora Harold

Chief Executive Officer at T-Therapeutics

Investor perspective

"This is a leadership team with an outstanding track record of building successful drug discovery businesses and translating science into medicines. Backed by a syndicate of world-class life sciences investors, T-Therapeutics is uniquely positioned to unlock previously undruggable targets with its first-in-class bispecifics. We are proud to support the team and help catalyse their programmes towards the clinic."

Luke Rajah

Partner, BGF